The importance of molecular monitoring in acute promyelocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 3, 2003, Pages 503-520

  Lo Coco, Francesco ^a   Breccia, Massimo ^b   Diverio, Daniela ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute promyelocytic leukaemia (APL); Minimal residual disease (MRD); PML RAR ; Reverse transcriptase polymerase chain reaction (RT PCR)

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CALICHEAMICIN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY M 195; NUCLEAR PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; PROMYELOCYTIC LEUKEMIA PROTEIN;

AUTOMATION; CANCER RECURRENCE; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CLINICAL TRIAL; FUSION GENE; GENE AMPLIFICATION; GENETIC MARKER; HEART ARRHYTHMIA; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MUCOSA INFLAMMATION; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; RETINOIC ACID SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; STANDARDIZATION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; CHEMOTHERAPY;

EID: 0041327674     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00041-0     Document Type: Article

References (85)

1. Grignani F, Fagioli M, Alcalay M et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10-25.
2. Chen S-J, Wang Z-Y & Chen Z. Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells 1995; 13: 22-31.
3. Warrell Jr. RP. Pathogenesis and management of acute promyelocytic leukemia. Annual Review of Medicine 1996; 47: 555-565.
4. Fenaux P, Chomienne C & Degos L. Acute promyelocytic leukemia: biology and treatment. Seminars in Oncology 1997; 24: 92-102.
5. Wiernik PH, Gallagher RE & Tallman MS. Diagnosis and treatment of acute promyelocytic leukemia. In Wiernik PH, Canellos GP, Dutcher JP & Kyle RA (eds) Neoplastic Diseases of the Blood, 3rd edn. New York: Churchill Livingstone, 1996, pp 353-380.
6. Lo Coco F, Nervi C, Avvisati A & Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998; 12: 1866-1880.
7. Tallman MS, Nabhan CH, Feusner JH & Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759-767.
8. Barbui T, Finazzi G & Falanga A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093-3102.
9. Di Bona E, Avvisati G, Castaman G et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. British Journal of Haematology 2000; 108: 689-695.
10. Bennett JM, Catowsky D, Daniel MT et al. Proposal for the classification of the acute leukaemias. British Journal of Haematology 1976; 33: 451-458.
11. Bennett JM, Catowsky D, Daniel MT et al. A variant form of hypergranular promyelocytic leukaemia. British Journal of Haematology 1980; 44: 169-170.
12. Mc Kenna RW, Parkin J, Bloomfield CD et al. Acute promyelocytic leukaemia; a study of 39 cases with identification of a hyperbasofilic microgranular variant. British Journal of Haematology 1982; 50: 201-214.
13. Tallman MS, Hakimian D, Snower D et al. Basophilic differentiation in acute promyelocytic leukemia. Leukemia 1993; 7: 521-526.
14. Guglielmi C, Martelli MP, Diverio D et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. British Journal of Haematology 1998; 102: 1035-1041.
15. Ferrara F, Morabito F, Martino B et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous ATRA and chemotherapy. Journal of Clinical Oncology 2000; 18: 1295-1300.
16. Murray CK, Estey E, Paietta E et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? Journal of Clinical Oncology 1999; 17: 293-297.
17. Grimwade D, Howe K, Langabeer S et al. Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia (APL): cytogenetic, molecular and PML-immunofluorescence assessment of patients entered into the MRC ATRA trial. British Journal of Haematology 1996; 94: 557-573.
18. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999; 93: 4131-4134.
19. Grimwade D, Biondi A, Mozziconacci M-J et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000; 96: 1297-1308.
20. Dyck J, Warrell RP, Evans RM et al. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML-RARα protein. Blood 1995; 86: 862-867.
21. Falini B, Flenghi L, Fagioli M et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3. Blood 1997; 90: 4046-4053.
22. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.
23. Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. British Journal of Haematology 1999; 106: 591-613.
24. Diverio D, Riccioni R, Pistilli A et al. Improved rapid detection of the PML-RARα fusion gene in acute promyelocytic leukemia. Leukemia 1996; 10: 1214-1216.
25. Cassinat B, Zassadowski F, Balitrand N et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-328.
26. Alcalay M, Zangrilli D, Fagioli M et al. Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1992; 89: 4840-4844.
27. Pandolfi PP, Alcalay A, Fagioli M et al. Genomic variability and alternative splicing generate multiple PML-RARα transcripts that encode aberrant PML proteins and PML-RARα isoforms in acute promyelocytic leukemia. EMBO Journal 1992; 11: 1397-1407.
28. Arnould C, Philippe C, Bourdon V et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia. Human Molecular Genetics 1999; 8: 1741-1749.
29. Zelent S-J, Tong J-H et al. Rearrangements of the retinoic acid receptor α and promyelocytic zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. Journal of Clinical Investigation 1993; 91: 2260-2267.
30. Chen Z, Brand NJ, Chen A et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO Journal 1993; 12: 1161-1167.
31. Redner RL, Rush EA, Faas S et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882-886.
32. Wells RA, Catzavelos C & Kamel-Reid S. Fusion of retinoic acid receptor α to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genetics 1997; 17: 109-113.
33. Licht JD, Chomienne C, Goy A et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11; 17). Blood 1995; 85: 1083-1094.
34. Koken MH, Daniel MT, Gianni M et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR(fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17) (q23;q21) APL patient. Oncogene 1999; 18: 1113-1118.
35. Vahdat L, Maslak P, Miller WH et al. Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: Impact of leucocytosis, low-dose chemotherapy, PML/RARα isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
36. Gallagher RE, Li Y-P, Rao S et al. Characterization of acute promyelocytic leukemia cases with PML/RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995; 86: 1540-1547.
37. Fukutani H, Naoe T, Ohno R et al. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 1995; 9: 1478-1482.
38. Gallagher RE, Willman CL, Slack JL et al. Association of PML/RARα fusion mRNA type with pre-treatment characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997; 90: 1656-1663.
39. Slack JL, Willman CL, Andersen JW et al. Molecular analysis and clinical outcome of adult APL patients with the V PML/RARα isoform: results from Intergroup protocol 0129. Blood 2000; 95: 398-403.
40. Gonzalez M, Barragan E, Bolufer P et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. British Journal of Haematology 2001; 114: 99- 103.
41. Seale JRC, Varma S, Swirsky DM et al. Quantification of PML/RARa transcript in acute promyelocytic leukaemia: explanation for lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia specific mRNA by alpha interferon. British Journal of Haemotology 1996; 95: 95-101.
42. Asou N, Adachi K, Tamura J et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. Journal of Clinical Oncology 1998; 16: 78-85.
43. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of ATRA followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
44. Mandelli F, Diverio D, Avvisati G et al. Molecular remission in PML/RARa positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014-1021.
45. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
46. Sanz MA, Lo Coco F, Martín G et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
47. Lengfelder E, Reichert A, Schoch C et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 2000; 14: 1362-1370.
48. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
49. Grimwade D, Diverio D, Harrison G et al. Detection of minimal residual disease (MRD) in APL by real-time RT-PCR: analysis of cases entered into the UK MRC ATRA trial. Blood 1999; 94(supplement 1): 625a.
50. Grimwade D, Howe K, Langabeer S et al. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61-66.
51. Tobal K, Saunders MJ, Grey MR & Yin JA. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. British Journal of Haematology 1995; 90: 615-618.
52. Tobal K, Liu Yin JA et al. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 1998; 12: 1349-1354.
53. Grimwade D. The significance of minimal residual disease in patients with t(15;17). Baillière's Clinical Haematology 2002; 15: 137-158.
54. Gabert J, Beillard E, van der Velden VHJ et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003;. in press.
55. Gallagher RE, Yeap BY, Wanli BI et al. Quantitative real time RT-PCR analysis of PML/RARa mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
56. Miller WH, Kakizuka A, Frankel SR et al. Reverse transription polymerase chain reaction for the rearrenged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the USA 1992; 89: 2694-2698.
57. Biondi A, Rambaldi A, Pandolfi PP et al. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
58. Castaigne S, Balitrand N, de Thè H et al. A PML/retinoic acid receptor a fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992; 79: 3110-3115.
59. Chang KS, Lu J, Wang G et al. The (15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene. Targets for the detection of minimal residual disease by PCR. Blood 1992; 79: 554-558.
60. Lo Coco F, Diverio D, Pandolfi PP et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992; 340: 1437-1438.
61. Miller WH, Levine K, DeBlasio A et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993; 82: 1689-1694.
62. Diverio D, Pandolfi PP, Biondi A et al. Absence of RT-PCR detectable residual disease in acute promyelocytic leukemia in long term remission. Blood 1993; 82: 1689-1694.
63. Fukutani H, Naoe T, Ohno R et al. Prognostic significance of the RT-PCR assay of PML/RARa transcripts in acute promyelocytic leukemia. Leukemia 1995; 9: 588-593.
64. Takatsuki H, Umemura T, Sadamura S et al. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RARa fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation. Leukemia 1995; 9: 889-892.
65. Román J, Martín C, Torres A et al. Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplantation 1997; 19: 679-683.
66. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter AIDA trial. Blood 1998; 92: 784-789.
67. Bolufer P, Barragán E, Sanz MA et al. Monitoring of minimal residual disease with the combined detection of PML/RAR alpha and RAR alpha/PML rearrangements in acute promyelocytic leukemia. Medicina Clinica (Barcelona) 2000; 114: 281-285.
68. Gameiro P, Vieira S, Silva CP et al. The PML-RARα transcript in long-term follow-up of acute promyelocytic leukaemia patients. Haematologica 2001; 86: 577-585.
69. Jurcic JG, Nimer SD, Scheinberg DA et al. Prognostic significance of minimal residual disease detection and PML/RARα isoform type: long term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
70. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
71. 3) in the treatment of acute promyelocytic leukemia (APL). II Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
72. Soignet SL, Maslack P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine 1998; 339: 1341-1348.
73. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in II newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
74. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 2001; 19: 3852-3860.
75. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARa fusion gene. Blood 1997; 90: 1321-1325.
76. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000; 14: 1006-1013.
77. Estey E, Giles FJ, Kantarjian H et al. Molecular remission induced by liposomal-encapsulated all-trans-retinoic acid in newly diagnosed acute promyelocytic leukaemia. Blood 1999; 94: 2230-2235.
78. Douer D, Estey E, Santillana S et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73-80.
79. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Clinical Review in Oncology and Hematology 2001; 38: 37-45.
80. Petti MC, Pinazzi B, Diverto D et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin. British Journal of Haematology 2001; 115:63-65.
81. Estey EH, Giles FJ, Beran M et al. Experience with gemtuzumab ozogamycin (mylotarg) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
82. Sanz MA, Martin G, Barragán E et al. All-trans retinoic acid and anthracycline reinforcement in consolidation improve the outcome of patients with intermediate and high-risk acute promyelocytic leukemia: results of the Spanish PETHEMA trial LPA99. Blood 2002; 100: 155a.
83. Latagliata R, Petti MC, Fenu S et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822-824.
84. Heid CA, Stevens J, Livak KJ & Williams PM. Real time quantitative PCR. Genome Research 1996; 6: 986-994.
85. Mitterbauer A, Mannhalter C, Jager U et al. Quantitation of minimal residual disease in acute promyelocytic leukemia (APL) by real time quantitative RT-PCR with specific fluorescent hybridization probes. Blood 2000; 94(supplement 1): 313a.